Filters
Term Search
You can select from the dropdown list OR enter your own terms to refine the search.
Last Updated: 10/31/2025
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 21 publications
Prolonged Progression-Free Survival, Disease-Free Survival and Cystectomy Avoidance with IL-15 Receptor Lymphocyte-Stimulating Agent NAI plus BCG in BCG-Unresponsive Papillary-Only NMIBC.
Journal: The Journal of urology
Published: September 16, 2025
Traditional and next-generation bacillus Calmette-Guérin based treatment strategies for bacillus Calmette-Guérin unresponsive non-muscle-invasive bladder cancer in the era of emerging therapies.
Journal: Current opinion in urology
Published: July 14, 2025
FDA Approval Summary: Nogapendekin Alfa Inbakicept-pmln with BCG for BCG-unresponsive carcinoma in situ.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: April 08, 2025
Current State of Bladder Preservation in High Grade Non-Muscle Invasive Bladder Cancer and Localized Muscle Invasive Bladder Cancer.
Journal: Current oncology reports
Published: February 26, 2025
Emerging bladder-sparing treatments for high risk non-muscle invasive bladder cancer.
Journal: Bladder cancer (Amsterdam, Netherlands)
Published: February 09, 2025
Nogapendekin alfa Inbakicept-pmln (Anktiva) with BCG: A Promising Arsenal in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer Intervention.
Journal: Advanced pharmaceutical bulletin
Published: October 13, 2024
Novel intravesical therapies and delivery systems for the management of bladder cancer.
Journal: Current opinion in urology
Published: October 08, 2024
Unmet Need in Non-muscle-invasive Bladder Cancer Failing Bacillus Calmette-Guérin Therapy: A Systematic Review and Cost-effectiveness Analyses from the International Bladder Cancer Group.
Journal: European urology oncology
Published: September 23, 2024
Transforming non-muscle invasive bladder cancer (NMIBC) treatment: FDA approval of Anktiva in combination with BCG.
Journal: Annals of medicine and surgery (2012)
Published: August 06, 2024
Case report: PD-L1-targeted high-affinity natural killer cells and IL-15 superagonist N-803-based therapy extend overall survival of advanced metastatic pancreatic cancer patients.
Journal: Frontiers in oncology
Published: July 29, 2024
Last Updated: 10/31/2025